139 related articles for article (PubMed ID: 28415776)
1. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.
Dunlop EA; Johnson CE; Wiltshire M; Errington RJ; Tee AR
Oncotarget; 2017 Jul; 8(30):48711-48724. PubMed ID: 28415776
[TBL] [Abstract][Full Text] [Related]
2. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Johnson CE; Dunlop EA; Seifan S; McCann HD; Hay T; Parfitt GJ; Jones AT; Giles PJ; Shen MH; Sampson JR; Errington RJ; Davies DM; Tee AR
Oncogene; 2018 Nov; 37(45):5913-5925. PubMed ID: 29980790
[TBL] [Abstract][Full Text] [Related]
3. Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.
Johnson CE; Hunt DK; Wiltshire M; Herbert TP; Sampson JR; Errington RJ; Davies DM; Tee AR
Mol Oncol; 2015 Mar; 9(3):675-88. PubMed ID: 25498902
[TBL] [Abstract][Full Text] [Related]
4. Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment.
McCann HD; Johnson CE; Errington RJ; Davies DM; Dunlop EA; Tee AR
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30308940
[TBL] [Abstract][Full Text] [Related]
5. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
7. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
8. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.
Valvezan AJ; Turner M; Belaid A; Lam HC; Miller SK; McNamara MC; Baglini C; Housden BE; Perrimon N; Kwiatkowski DJ; Asara JM; Henske EP; Manning BD
Cancer Cell; 2017 Nov; 32(5):624-638.e5. PubMed ID: 29056426
[TBL] [Abstract][Full Text] [Related]
10. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress.
Young RM; Ackerman D; Quinn ZL; Mancuso A; Gruber M; Liu L; Giannoukos DN; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Genes Dev; 2013 May; 27(10):1115-31. PubMed ID: 23699409
[TBL] [Abstract][Full Text] [Related]
12. Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2
Nishikawa K; Mezawa Y; Kobayashi T
Genes Cells; 2023 Jun; 28(6):447-456. PubMed ID: 36965015
[TBL] [Abstract][Full Text] [Related]
13. Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkers.
Bhaoighill MN; Falcón-Pérez JM; Royo F; Tee AR; Webber JP; Dunlop EA
J Extracell Vesicles; 2023 Jun; 12(6):e12336. PubMed ID: 37337371
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
Krishnamoorthy J; Tenkerian C; Gupta J; Ghaddar N; Wang S; Darini C; Staschke KA; Ghosh A; Gandin V; Topisirovic I; Kristof AS; Hatzoglou M; Simos G; Koromilas AE
Cell Death Dis; 2018 Feb; 9(3):254. PubMed ID: 29449538
[TBL] [Abstract][Full Text] [Related]
15. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner.
Bilanges B; Argonza-Barrett R; Kolesnichenko M; Skinner C; Nair M; Chen M; Stokoe D
Mol Cell Biol; 2007 Aug; 27(16):5746-64. PubMed ID: 17562867
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
18. Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies.
Posey KL; Coustry F; Veerisetty AC; Hossain MG; Gambello MJ; Hecht JT
Am J Pathol; 2019 Jan; 189(1):132-146. PubMed ID: 30553437
[TBL] [Abstract][Full Text] [Related]
19. Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing
Klover PJ; Thangapazham RL; Kato J; Wang JA; Anderson SA; Hoffmann V; Steagall WK; Li S; McCart E; Nathan N; Bernstock JD; Wilkerson MD; Dalgard CL; Moss J; Darling TN
Elife; 2017 Jul; 6():. PubMed ID: 28695825
[TBL] [Abstract][Full Text] [Related]
20. Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.
Bai Y; Xuan B; Liu H; Zhong J; Yu D; Qian Z
J Virol; 2015 Aug; 89(15):7625-35. PubMed ID: 25972538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
